CIRIUM
Cirium , the aviation analytics company, and travel data analytics firm, 3Victors today announced a reseller partnership to enable Cirium to bring together flight schedules and passenger traffic data with online search data to interpret, understand and forecast passenger demand for airports and DMOs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005656/en/
“Cirium and 3Victors share the mission to revolutionize the way the travel industry forecasts future demand,” said Kim Gesch, VP Airline Planning at Cirium. “Airlines and airports worldwide have long used the Diio by Cirium suite of products for network and traffic analysis. We have invested in the products and have enhanced the quality of our schedules, traffic, and fares data to ensure we maintain our leading position in the market.”
Chris Zando, CEO at 3Victors said: “Both 3Victors and Cirium are focused on high quality data science to bring real-time insights to commercial decision-making for the industry. The combination of both our capabilities provides the most dynamic forecasting in the market and at a time when it is most needed.”
Travel demand models have traditionally been built by comparing current bookings for flights against historical trends. Ticket prices were raised and lowered based on indicators from these models to ensure a flight was booked at optimum fare levels. Post-pandemic, changes to traveler booking behavior means past booking patterns may no longer be reliable as a guide to future demand.
Cirium and 3Victors will join forces to offer the most complete solution for analyzing future traffic, monitoring trends across time and detecting emerging opportunities. The offering will include the Diio by Cirium flight schedules, traffic and fares data alongside 3Victors DemandView search data, providing the most accurate forecast as possible.
This is particularly important for airports seeking better insights to retain and gain air service or DMOs wanting to optimize their marketing campaigns and traveler conversion rates.
3Victors’ search data is captured from more than half a million global touchpoints, including when a prospective traveler visits traditional or online travel agency, meta search, or travel search engine: or searches for flights. The most advanced data science is applied to interpret the traveler behavior, which provides a clear demand signal for flight bookings.
An example using 3Victors data shows that on a recent date there were large spikes in domestic demand originating in the UK and US, along with output showing year-over-year variation. If historical trends alone were used to forecast travel demand, the spikes in travel being seen in 2022 to date would not have been forecast.
Said Cirium’s Gesch: “Pairing Cirium’s capabilities with 3Victors’ contemporary travel demand insights means we can offer clients worldwide the most advanced solution to determine accurate traveler intent, monitor passenger trends, and identify correlations between what travelers are searching and actually booking.”
Ends
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com
About 3Victors
3Victors has built the industry’s first travel data analytics as a service platform in the Cloud. 3V’s proprietary 360° view of the travel landscape is the nexus between data volume, variety and velocity. 3V delivers market-leading data coverage and real-time analytics and insights, empowering companies with actionable intelligence.
For further information please follow 3Victors on LinkedIn or visit https://www.3victors.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005656/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom